Randomized, Double-blind, Placebo-controlled Trial Investigating the Role of a Personal Care Product on Vaginal Health

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Clinical Phase

NA

Total Enrollment

70 participants

Study Classification

INTERVENTIONAL

Study Start Date

2022-12-05

Study Completion Date

2023-05-15

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

The goal of this clinical trial is to assess the impact of a personal care product on vaginal health in a healthy participant population. The personal care product, VM-02, contains a prebiotic, postbiotic, and three distinct strains of Lactobacillus crispatus, a microbe commonly found in healthy females, together accounting for greater than 85% of known genes in this species. The intervention will be compared to a placebo intervention and will aim to assess the following in a healthy female population:

Measure changes in the relative and absolute abundance of a bacterial species, Lactobacillus crispatus, in the vagina, compared the baseline (prior to use of the personal care product) to two time points after use.

Observe changes in vaginal pH and self-reported discomfort from vaginal odor, compared the baseline to two time points after use.

Determine the user experience of three variations of a personal care product administered in different formats to improve vaginal health and establish tolerability and user acceptability.

Participants will use the personal care product according to a specific program as directed, conduct vaginal swab sampling, and answer questionnaires, each at eight time points.

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

Evaluation of the Vaginal Colonization of Two New Lactobacillus Strains After Oral Administration in Healthy Volunteers

NCT05688397

Healthy

COMPLETED NA

Clinical Trial to Evaluate the Effect of an Oral Probiotic on the Vaginal Flora

NCT03923985

Vaginal Flora

COMPLETED NA

Effects of Lactobacillus Crispatus LCr86 on Bacterial Vaginosis and Ovarian Function in Women

NCT06830122

Patients With Bacterial Vaginosis

NOT_YET_RECRUITING NA

Safety Study of Lactobacillus Administered Vaginally to Healthy Women

NCT00537576

Bacterial Vaginosis

COMPLETED PHASE1

Effects of Lacticaseibacillus Rhamnosus LRa05 on Bacterial Vaginosis and Ovarian Function in Women

NCT06821789

Patients With Bacterial Vaginosis

NOT_YET_RECRUITING NA

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

The vaginal microbiome is a dynamic microecosystem that undergoes fluctuations during the female menstrual cycle and at various life stages from puberty to menopause. A healthy vaginal microbiome is dominated by Lactobacillus which regulates vaginal pH, produces antimicrobial compounds, and significantly influences host immune response. The purpose of this study is to determine whether vaginal health can be influenced by a novel personal care product comprised of a Lactobacillus postbiotic, prebiotic, and multiple strains of Lactobacillus crispatus predictive of a stable vaginal microbiome.

This study will be a randomized double-blind, placebo-controlled intervention that will examine the safety and tolerability of a personal care product for vaginal health, VM-02. This pilot study will last for the duration of two complete menstrual cycles. Data will be collected via participant virtual questionnaires and vaginal swabs.

Participants are randomized as follows:

A two-arm randomized, double-blind, placebo-controlled study to evaluate VM-02 as a vaginal suppository capsule.

Arm #1: Vaginal application of single-use applicators filled with a vaginal suppository capsule at 5 x 10\^8 CFU/dose. The study product will be administered once daily for 7 consecutive days, followed by once weekly application over 2 consecutive additional weeks.

Arm #2: Vaginal application of single-use applicators filled with a vaginal suppository placebo capsule. The study product will be administered once daily for 7 consecutive days, followed by once weekly application over 2 consecutive additional weeks.

Three additional arms are included to quantify the impact of an alternative formulation and user experience.

Arm #3: Vaginal application of single-use applicators filled with vaginal suppository tablet at 5 x 10\^8 CFU/dose. The study product will be administered on Days 1,4,7,14,21.

Arm #4: Oral administration of capsule at 5 x 10\^8 cfu/dose. The study product will be administered daily for 30 consecutive days.

Arm #5: Oral administration of commercially available over-the-counter oral capsule at 5 x 10\^8 CFU/dose. The study product will be administered daily for 30 consecutive days.

Colonization rate of 3 distinct Lactobacillus crispatus after administration of VM-02 will be assessed with PCR and DNA sequence analysis.

Researchers will compare groups who received active product with those who received a placebo (a look-alike substance that contains no active drug) to determine product safety and any possible side effects, see if the amount of the bacterial species, Lactobacillus crispatus, changes (either increases or decreases) in response to the treatment, and to determine any impacts on self-reported odor and vaginal health.

A total of 80 participants will be recruited for this study. All participants will be supported and tracked through the various stages of the study virtually. All biomarker swabs that are taken by participants will be returned via pre-paid envelopes provided by the research team and all survey information will be collected online. No in-person visits will be required. Participants who are unwilling to follow the study protocol will be removed from the study.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Vaginal Personal Care

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

RANDOMIZED

Intervention Model

SINGLE_GROUP

Primary Study Purpose

BASIC_SCIENCE

Blinding Strategy

QUADRUPLE

Participants Caregivers Investigators Outcome Assessors

Due to this study being double-blind, participants will not know if they are in the condition with the test product or the placebo. Neither the test products nor the placebo used during the study will be labeled in any way that will indicate whether participants are taking the placebo or the test product. Participants will just know there is a chance they were randomized into a placebo or test product arm of the study. As mentioned above, only the Research Coordinator will know which group the participant is randomized into. The PI will remain blinded throughout the study.

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Vaginal Suppository Capsule

In the VM-02 Vaginal Suppository Capsule Placebo Arm, participants will take the test vaginal suppository capsule placebo as directed.

Group Type PLACEBO_COMPARATOR

VM-02 Placebo

Intervention Type OTHER

VM-02 Placebo is a personal care product placebo for vaginal health.

Vaginal Suppository Capsule Active

In the VM-02 Vaginal Suppository Capsule Active Arm, participants will take a test vaginal suppository capsule as directed.

Group Type EXPERIMENTAL

VM-02

Intervention Type OTHER

VM-02 is a personal care product for vaginal health.

Vaginal Suppository Tablet Active

In the VM-02 Vaginal Suppository Tablet Active Arm, participants will take a test vaginal suppository tablet as directed.

Group Type EXPERIMENTAL

VM-02

Intervention Type OTHER

VM-02 is a personal care product for vaginal health.

Oral Capsule Active

In the VM-02 Oral Capsule Active Arm, participants will take a test oral capsule as directed.

Group Type EXPERIMENTAL

VM-02

Intervention Type OTHER

VM-02 is a personal care product for vaginal health.

Commercial Oral Vaginal Probiotic Competitor

In the Commercial Over-The-Counter (OTC) Oral Probiotic Competitor Arm, participants will take an over-the-counter competitor product as directed.

Group Type OTHER

Commercial Oral Probiotic Competitor

Intervention Type DIETARY_SUPPLEMENT

Commercial Oral Vaginal Probiotic Competitor is a personal care product for vaginal health.

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

VM-02

VM-02 is a personal care product for vaginal health.

Intervention Type OTHER

Commercial Oral Probiotic Competitor

Commercial Oral Vaginal Probiotic Competitor is a personal care product for vaginal health.

Intervention Type DIETARY_SUPPLEMENT

VM-02 Placebo

VM-02 Placebo is a personal care product placebo for vaginal health.

Intervention Type OTHER

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Reproductive age women aged ≥ 18.
* History of regular menses every 21-35 days for six months prior to the study.
* Agreement not to use specified intra-vaginal products during the study product use.
* Willing to use an intra-vaginal suppository or dietary supplement during the study period.
* Willing to complete vaginal swabs on themselves as directed in the study.
* Ability to understand and read English and provide written consent.

Exclusion Criteria

* Pregnancy or planned pregnancy in the next 6 months.
* Two or more amenorrheic months in the past 6 months.
* Lives in the state of New York.
* Allergy to any components of the supporting or excipient ingredients in test formulation capsules, tablets, placebos or over-the-counter competitor product.

Minimum Eligible Age

18 Years

Eligible Sex

FEMALE

Accepts Healthy Volunteers

Yes